Erythrocytic calpain-calpastatin system in Alzheimer's disease

Aging Clinical and Experimental Research

Volumn 8, Issue 2, 1996, Pages 106-108

  Soldati, L ^a   Alberoni, M ^b   Bianchi, G ^a   Canal, N ^b   Franceschi, M ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Alzheimer's disease; Calpains; Calpastatin

Indexed keywords

BIOCHEMICAL MARKER; CALPAIN; CALPASTATIN;

ADULT; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; ERYTHROCYTE; FEMALE; HUMAN; MALE;

EID: 0029893628     PISSN: 03949532     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03339563     Document Type: Article

References (14)

1. Selkoe D.J.: Biochemistry of Alzheimer's disease. In: Siegel G.J (Ed.), Basic Neurochemistry. Molecular, Cellular and Medical Aspects, ed. 5. Raven Press, New York, 1994, pp 919-933.
2. Siman R., Card J P., Davis L.G.: Proteolytic processing of beta-amyloid precursor by Calpain I. J. Neurosci. 10: 2400-2411, 1990.
3. Zimmermann U J.P., Schlaepfer W.W.: Characterization of a brain calcium-activated proteases that degrades neurofilament proteins. Biochem 21: 3977-3983, 1982.
4. Murachi T.: Calpain and calpastatin. Trends Biochem. Sci. 88: 167-169, 1983.
5. Melloni E., Pontremoli S., The Calpains. Trends Neurosci. 12. 438-444, 1989.
6. Lynch G , Baudry M.: Brain spectrin. calpain and long-term changes in synaptic efficacy. Brain Res. Bull 18: 809-815, 1987.
7. Del Cerro S., Larson J., Oliver M.W., Lynch G. Development of hippocampal long-term potentiation is reduced by recently introduced calpain inhibitors. Brain Res. 530: 91-95, 1990.
8. 2+-activated proteinase enzyme and endogenous inhibitor activity in brain tissue from normal and Alzheimer s disease cases J. Neurol Sci. 102: 220-224, 1991.
9. Saito K I., Elce J.S , Hamos J.E., Nixon R.A.: Widespread activation of calcium-activated neutral proteinase (calpain) in the brain in Alzheimer disease: A potential molecular basis for neuronal degeneration. Proc. Natl. Acad. Sci. USA 90: 2628-2632, 1993
10. Nilsson E , Alafuzoff I., Blennow K., Blomgren K., Hall C.M., Jansson I., Karlsson I., Wallin A., Gottfries C.G., Karlsson J.O : Calpain and calpastatin in normal and Alzheimer-degenerated human brain tissue. Neurobiol. Aging 11: 425-431, 1990.
11. Karlsson J O , Blennow K , Holmberg B., Janson I., Karlsson I., Nilsson E., Wallin A., Gottfries C.G : Increased proteolytic activity in erythrocytes from patients with Alzheimer's disease. Dementia 3: 200-204, 1992.
12. McKhann G , Drachman D., Folstein M , Katzman R , Price D., Stadlan E M.: Clinical diagnosis of Alzheimer s disease: report of the NINCDS-ADRDA work group under the auspices of Department of health and human services task force on Alzheimer's disease Neurology 34 939-944, 1984
13. Pontremoli S., Melloni E., Salamino F., Sparatore B., Viotti P., Michetti M. Duzzi L., Bianchi G Decreased level of calpain inhibitor in red blood cells from Milan hypertensive rats. Biochem. Biophys. Res. Commun. 3: 1370-1375, 1986.
14. Kenessey A., Banay-Schwartz M., De Guzman T., Lajtha A.: Calpain II activity and calpastatin content in brain regions of 3-and 24-old rats. Neurochem. Res 15: 243-249, 1990.